Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
Primary Objectives: To evaluate the effect of the subjects with mild (Child Pugh A), moderate (Child Pugh B) and normal hepatic impairment on the pharmacokinetics of YZJ-1139 Secondary Objectives: To evaluate the safety of a single oral dose of YZJ-1139 in subjects with mild, moderate and normal hepatic impairment
Epistemonikos ID: 2fe9cfebbaf786b9bb465cd3b4a8f04a938fed11
First added on: Dec 01, 2024